DE60032517D1 - Heilmittel gegen durch endothelin verursachte erkrankungen - Google Patents

Heilmittel gegen durch endothelin verursachte erkrankungen

Info

Publication number
DE60032517D1
DE60032517D1 DE60032517T DE60032517T DE60032517D1 DE 60032517 D1 DE60032517 D1 DE 60032517D1 DE 60032517 T DE60032517 T DE 60032517T DE 60032517 T DE60032517 T DE 60032517T DE 60032517 D1 DE60032517 D1 DE 60032517D1
Authority
DE
Germany
Prior art keywords
agents against
against endothelin
diseases
endothelin diseases
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60032517T
Other languages
English (en)
Other versions
DE60032517T2 (de
Inventor
Hironori Yuyama
Akira Fujimori
Masanao Sanagi
Hironori Harada
Akiko Koakutsu
Mikiko Mori
Nobuyuki Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of DE60032517D1 publication Critical patent/DE60032517D1/de
Publication of DE60032517T2 publication Critical patent/DE60032517T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60032517T 2000-02-16 2000-10-27 Heilmittel gegen durch endothelin verursachte erkrankungen Expired - Fee Related DE60032517T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000037313 2000-02-16
JP2000037314 2000-02-16
JP2000037314 2000-02-16
JP2000037313 2000-02-16
PCT/JP2000/007573 WO2001060370A1 (fr) 2000-02-16 2000-10-27 Remedes contre les maladies induites par l'endotheline

Publications (2)

Publication Number Publication Date
DE60032517D1 true DE60032517D1 (de) 2007-02-01
DE60032517T2 DE60032517T2 (de) 2007-10-04

Family

ID=26585418

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60032517T Expired - Fee Related DE60032517T2 (de) 2000-02-16 2000-10-27 Heilmittel gegen durch endothelin verursachte erkrankungen

Country Status (15)

Country Link
US (1) US6774131B1 (de)
EP (1) EP1256344B1 (de)
JP (2) JP3832229B2 (de)
KR (1) KR20020075797A (de)
CN (1) CN1434715A (de)
AR (1) AR031679A1 (de)
AT (1) ATE348617T1 (de)
AU (1) AU2000279614A1 (de)
BR (1) BR0017120A (de)
CA (1) CA2395711A1 (de)
DE (1) DE60032517T2 (de)
ES (1) ES2277856T3 (de)
HU (1) HUP0204139A3 (de)
RU (1) RU2002124599A (de)
WO (1) WO2001060370A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
GB0219660D0 (en) * 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
BRPI0806418A2 (pt) * 2007-02-09 2011-09-06 Poniard Pharmaceuticals Inc formas de dosagem oral para picoplatina, série de granulados revestidos, processo para preparar uma forma de dosagem oral para picoplatina e métodos de tratamentos do cáncer
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
WO2009011861A1 (en) * 2007-07-16 2009-01-22 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
WO2009099649A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer
EP2294056A1 (de) * 2008-05-23 2011-03-16 Synthon B.V. Bosentansalze
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US20140105918A1 (en) 2012-10-12 2014-04-17 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2172735C2 (ru) 1995-12-20 2001-08-27 Яманоути Фармасьютикал Ко., Лтд. Арилэтенсульфонамидные производные и фармацевтическая композиция
US6030975A (en) * 1997-03-14 2000-02-29 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use in treating cancer
US6673832B1 (en) 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain

Also Published As

Publication number Publication date
JP2006176542A (ja) 2006-07-06
HUP0204139A2 (en) 2003-05-28
RU2002124599A (ru) 2004-03-10
CN1434715A (zh) 2003-08-06
EP1256344A1 (de) 2002-11-13
BR0017120A (pt) 2003-01-14
DE60032517T2 (de) 2007-10-04
AR031679A1 (es) 2003-10-01
JP3832229B2 (ja) 2006-10-11
EP1256344A4 (de) 2004-12-29
WO2001060370A1 (fr) 2001-08-23
ES2277856T3 (es) 2007-08-01
AU2000279614A1 (en) 2001-08-27
KR20020075797A (ko) 2002-10-05
CA2395711A1 (en) 2002-07-18
US6774131B1 (en) 2004-08-10
ATE348617T1 (de) 2007-01-15
EP1256344B1 (de) 2006-12-20
HUP0204139A3 (en) 2003-07-28
JP2001302514A (ja) 2001-10-31

Similar Documents

Publication Publication Date Title
DE60133144D1 (de) Reinigungsartikel
DE60125876D1 (de) Ultraschalleinsatz
DE60138102D1 (de) Antikörper gegen menschliches mcp-1
IS6779A (is) Mannlíkt mótefni gegn LT-beta-R
DE60128599D1 (de) Arbeitsgerät
NO20031869L (no) Antiinflammatoriske midler
FI20001993A0 (fi) Puhelinneuvottelu
DE60107598D1 (de) Smart-skin strukturen
DE60135271D1 (de) Reinigungsmittel
DE60032517D1 (de) Heilmittel gegen durch endothelin verursachte erkrankungen
DE60125945D1 (de) Nasenspüler und dessen auslassstück
DE10196135T1 (de) Port-Paket-Warteschlangenbildung
NO20011872L (no) Dispergeringer
DE50104507D1 (de) Reinigungs- und desinfektionsmittel
DE60135055D1 (de) Reinigungsmittel
DE60111787D1 (de) Reinigungsmittel
DE60129802D1 (de) Haushaltszünder
DE60139735D1 (de) Reinigungsartikel
DE50113112D1 (de) Schaltungsanordnung
FR2805983B3 (fr) Douche
ATE305217T1 (de) Ortho-phenylphenolat-konzentrate
DE50208656D1 (de) Kopfaufpralloptimierte frontstruktur
ATE295687T1 (de) Gegen pflanzenkrankheiten verwendbare pseudomycine
DK200000305U3 (da) Ultralydapparat
DE50115426D1 (de) Schaltungsanordnung

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: YUYAMA,HIRONORI YAMANOUCHI PHARMACEU, TSUKUBA-, JP

Inventor name: FUJIMORI, AKIRA YAMANOUCHI PHARMACEUTICAL CO.,, JP

Inventor name: SANAGI, MASANAO YAMANOUCHI PHARMACEUTICAL CO, , JP

Inventor name: HARADA, HIRONORI, TSUKUBA-SHI, IBARAKI 305-858, JP

Inventor name: KOAKUTSU, AKIKO, TSUKUBA-SHI, IBARAKI 305-8585, JP

Inventor name: MORI, MIKIKO, TSUKUBA-SHI, IBARAKI 305-8585, JP

Inventor name: YAMAMOTO, NOBUYUKI, ITABASHI-KU, TOKYO 174-861, JP

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee